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  EVIDENCE-BASED ANSWER 
Evidence from clinical trials supports the use of pneumococcal polysaccharide vaccine for prevention of 
pneumonia in nursing home patients (strength of recommendation: B, based on randomized, nonblinded 
clinical trials). 
Case-control studies have consistently shown the efficacy of pneumococcal vaccine in preventing invasive 
pneumococcal disease and bacteremia for patients with chronic medical illnesses and the elderly, patients 
typically found in nursing home populations (SOR: B, based on consistent case-control studies). 
  EVIDENCE SUMMARY 
Two clinical trials directly addressed the prevention of pneumonia in nursing home patients. A prospective, risk-
stratified, randomized study of the 14-valent pneumococcal vaccine in 1686 patients living in hospices and 
nursing homes in France showed an absolute risk reduction (ARR) of 2.9% in the incidence of all-cause 
pneumonia, corresponding to a number needed to treat (NNT) of 35.1 This study has 2 major limitations: the 
authors did not comment on whether the study was blinded, and 31% of patients were lost to follow-up. 
A 6-year randomized clinical trial that studied the trivalent pneumococcal vaccine in preventing pneumonia in 
New York City Home (a nursing home) subjects showed an ARR=2.7% and NNT=37.2 While this report also 
did not specify whether there was blinding, any bias introduced by absence of blinding is unlikely to account for 
the large effect size (relative risk reduction=0.56). 
Nursing home residents may be especially vulnerable to acquiring pneumococcal infection due to advanced 
age, chronic illnesses, and their communal setting. The Centers for Disease Control and Prevention (CDC) has 
reported outbreaks of invasive pneumococcal disease in nursing homes where vaccination rates are low.3 
Pneumococcal bacteremia is seen in only 10%–20% of patients with pneumococcal pneumonia but confers a 
significant risk of death. Therefore, pneumococcal vaccination is indicated for patients ≥ 65 years or those with 
chronic medical conditions. 
Case-control studies have consistently shown efficacy in preventing invasive pneumococcal disease. Farr and 
colleagues found efficacy of 70% (95% confidence interval [CI], 37%–86%) among 2 groups of patients: those 
≥ 2 years of age with chronic disease or those ≥ 65 years.4 A case-control study by Sims and colleagues also 
found the vaccine to have efficacy of 70% (95% CI, 37%– 86%) in preventing invasive pneumococcal disease 
in immunocompetent patients aged ≥ 55 years.5 
  RECOMMENDATIONS FROM OTHERS 
The CDC Advisory Committee on Immunization Practices (ACIP) recommends pneumococcal vaccination of 
persons aged ≥65 years and those aged 2 to 64 who have chronic cardiovascular disease, chronic pulmonary 
disease, or diabetes mellitus (SOR: A).6 
The ACIP also recommends the pneumococcal vaccine for persons aged 2 to 64 years who have alcoholism, 
chronic liver disease, or cerebrospinal fluid leaks (SOR: B). 
The Canadian Task Force on Preventive Health Care endorses vaccination for immunocompetent patients 55 
years residing in institutions (SOR: A).7 
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The importance of pneumococcal vaccine for the elderly is well established. However, the 
vaccine is underused in long-term care settings, despite being indicated for most 
residents. 
Patient confusion about the need for both influenza and pneumococcal vaccines, poor 
documentation of adult immunization status, poor availability of records from previous care 
facilities, and frequent changes in physician all contribute to low vaccination rates. 
An optimal strategy to ensure high vaccination rates is to administer the pneumococcal 
vaccine to patients on admission to long-term care facilities. Patients who are uncertain 
about their vaccination status may safely receive the vaccine, as revaccination is relatively 
well tolerated.8 
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